Current News

Contact | Print version | PDF version | Send article | RSS-Feed

DSM and Crucell Announce PER.C6 Technology Milestone

13 Mar 2008 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Crucell N.V. announced that another important milestone has been achieved with the PER.C6® technology platform for the production of monoclonal antibodies and recombinant proteins. Scientists working at PERCIVIA reached a record level titer of 15 g/L at harvest for an antibody product. PERCIVIA is the PER.C6® Development Center joint venture between DSM and Crucell, located in Cambridge, Massachusetts, USA.
 
Marco Cacciuttolo, CEO of PERCIVIA comments, "This high titer achievement for PER.C6®, the highest reported to date, marks a major event for the biopharmaceutical industry. It demonstrates the power and robustness of the PER.C6® manufacturing platform and it clearly shows that the PER.C6® manufacturing platform will have a major impact to the overall economics of manufacturing biopharmaceuticals. DSM and Crucell recognized the enormous potential of the PER.C6® technology when starting the PERCIVIA joint venture just over 1 year ago. The breakthrough results achieved in a single year reinforce the special properties and abilities of the PER.C6® manufacturing platform. Based on our scientific data today, we are confident that we will be able to drive productivity even further."